Legion Partners Asset Management LLC Has $15.23 Million Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Legion Partners Asset Management LLC increased its holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 0.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,968,409 shares of the company’s stock after purchasing an additional 18,182 shares during the period. Lifecore Biomedical makes up about 4.7% of Legion Partners Asset Management LLC’s investment portfolio, making the stock its 8th largest position. Legion Partners Asset Management LLC owned about 9.79% of Lifecore Biomedical worth $15,228,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Greenhaven Road Investment Management L.P. increased its holdings in shares of Lifecore Biomedical by 7.9% in the 4th quarter. Greenhaven Road Investment Management L.P. now owns 2,366,956 shares of the company’s stock worth $14,652,000 after buying an additional 173,623 shares during the last quarter. DCF Advisers LLC raised its position in Lifecore Biomedical by 115.1% during the fourth quarter. DCF Advisers LLC now owns 259,684 shares of the company’s stock valued at $1,607,000 after purchasing an additional 138,930 shares during the period. Oppenheimer Asset Management Inc. lifted its stake in shares of Lifecore Biomedical by 79.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 43,001 shares of the company’s stock valued at $228,000 after purchasing an additional 19,094 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Lifecore Biomedical in the 1st quarter worth approximately $58,000. Finally, Boston Partners bought a new position in shares of Lifecore Biomedical during the 1st quarter valued at approximately $104,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Craig Hallum started coverage on Lifecore Biomedical in a research report on Thursday, September 5th. They issued a “buy” rating and a $8.00 price target for the company. Barrington Research lowered shares of Lifecore Biomedical from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 28th.

Lifecore Biomedical Trading Down 0.4 %

LFCR opened at $4.72 on Friday. The company has a debt-to-equity ratio of 12.90, a quick ratio of 1.06 and a current ratio of 2.08. The stock’s 50 day moving average price is $5.26 and its 200-day moving average price is $5.63. Lifecore Biomedical, Inc. has a one year low of $3.68 and a one year high of $8.90. The stock has a market cap of $143.12 million, a price-to-earnings ratio of -1.41 and a beta of 0.95.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Monday, August 26th. The company reported ($0.15) EPS for the quarter. Lifecore Biomedical had a net margin of 9.37% and a negative return on equity of 515.12%. The business had revenue of $37.89 million during the quarter. On average, equities analysts forecast that Lifecore Biomedical, Inc. will post -0.89 EPS for the current year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.